Advertisement
UK markets close in 8 hours 9 minutes

  • FTSE 100

    8,298.78
    +85.29 (+1.04%)
     

  • FTSE 250

    20,296.13
    +131.59 (+0.65%)
     

  • AIM

    774.37
    +2.84 (+0.37%)
     

  • GBP/EUR

    1.1651
    -0.0009 (-0.07%)
     

  • GBP/USD

    1.2544
    -0.0019 (-0.15%)
     

  • Bitcoin GBP

    50,750.21
    -436.37 (-0.85%)
     

  • CMC Crypto 200

    1,367.85
    +2.72 (+0.20%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CRUDE OIL

    78.51
    +0.03 (+0.04%)
     

  • GOLD FUTURES

    2,327.40
    -3.80 (-0.16%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,482.00
    -96.30 (-0.52%)
     

  • DAX

    18,264.71
    +89.50 (+0.49%)
     

  • CAC 40

    8,043.02
    +46.38 (+0.58%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Compared to Estimates, LabCorp (LH) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

LabCorp (LH) reported $3.78 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 3.1%. EPS of $3.82 for the same period compares to $6.11 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $3.75 billion, representing a surprise of +0.87%. The company delivered an EPS surprise of -4.26%, with the consensus EPS estimate being $3.99.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how LabCorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Drug Development: $1.40 billion versus $1.52 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4% change.

  • Revenues- Diagnostics: $2.38 billion versus the four-analyst average estimate of $2.28 billion. The reported number represents a year-over-year change of -2.9%.

  • Adjusted Operating Income- Drug Development: $123.90 million compared to the $185.31 million average estimate based on three analysts.

  • Adjusted Operating Income- Diagnostics: $441.50 million compared to the $558.66 million average estimate based on three analysts.

View all Key Company Metrics for LabCorp here>>>

Shares of LabCorp have returned +5.8% over the past month versus the Zacks S&P 500 composite's +4.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research